US Stock MarketDetailed Quotes
RVPH Reviva Pharmaceuticals
- 1.120
- -0.030-2.61%
Close Nov 26 16:00 ET
- 1.160
- +0.040+3.56%
Post 16:37 ET
37.45MMarket Cap-1037P/E (TTM)
1.160High1.085Low444.39KVolume1.150Open1.150Pre Close497.37KTurnover1.92%Turnover RatioLossP/E (Static)33.44MShares5.67052wk High-3.76P/B25.87MFloat Cap0.60052wk Low--Dividend TTM23.10MShs Float15.100Historical High--Div YieldTTM6.52%Amplitude0.530Historical Low1.119Avg Price1Lot Size
Reviva Pharmaceuticals Stock Forum
Sign in to post a comment
$Alta Global Group (MMA.US)$ $Reviva Pharmaceuticals (RVPH.US)$ $Qualigen Therapeutics (QLGN.US)$ $NOVONIX (NVX.US)$ $Medicus Pharma (MDCX.US)$ $Hepion Pharmaceuticals (HEPA.US)$ $Purple Biotech (PPBT.US)$ $Eterna Therapeutics (ERNA.US)$ $Elong Power (ELPW.US)$ $Venus Concept (VERO.US)$ $Biofrontera (BFRI.US)$ $Exicure (XCUR.US)$
📊⚡️📊
📊⚡️📊
2
1
$Reviva Pharmaceuticals (RVPH.US)$ well i gave this play out a while ago anyone knows me knows i know this ticker for past few years.. nice moves today, will read and catch up on it, volume light, market conditions not great but 40% pretty good day so far.. will be on radar next year as well
$Reviva Pharmaceuticals (RVPH.US)$ primed for a big move soon
2
$Reviva Pharmaceuticals (RVPH.US)$
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia –
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOB...
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia –
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOB...
1
$Reviva Pharmaceuticals (RVPH.US)$
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Closing of $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
4
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Pharmaceuticals Holdings, Inc. -Topline Data From 1-Year Open-Label Extension (Ole) Trial Expected in Q4 2024
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Alignment With FDA On Brilaroxazine Clinical Trials For NDA In Schizophrenia; FDA Accepts 4-Week RECOVER-2 Study
2
$Reviva Pharmaceuticals (RVPH.US)$ H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) today and set a price target of $20.00.
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Stock_Drift OP T-24Century : What’s that ?